System Organ Class Preferred Term

Placebo (N=32)

5mg CCX140-B (N=63)

10mg CCX140-B (N=32)

30mgPioglitazone (N=32)

Subjects reporting any adverse events—no. (%)

6 (19.4)

19 (30.2)

6 (19.4)

7 (22.6)

Subjects with adverse events by system organ class with an incidence of ≥ 3% in any treatment group—no. (%)

Gastrointestinal disorders

2 (6.5)

10 (15.9)

1 (3.2)

2 (6.5)

Nausea

0 (0.0)

1 (1.6)

1 (3.2)

0 (0.0)

Constipation

0 (0.0)

2 (3.2)

0 (0.0)

0 (0.0)

Diarrhea

1 (3.2)

2 (3.2)

0 (0.0)

2 (6.5)

Dry mouth

1 (3.2)

1 (1.6)

0 (0.0)

0 (0.0)

Dyspepsia

0 (0.0)

2 (3.2)

0 (0.0)

0 (0.0)

Flatulence

0 (0.0)

2 (3.2)

0 (0.0)

0 (0.0)

Infections

3 (9.7)

3 (4.8)

1 (3.2)

1 (3.2)

Nasopharyngitis

2 (6.5)

1 (1.6)

1 (3.2)

0 (0.0)

Influenza

0 (0.0)

0 (0.0)

0 (0.0)

1 (3.2)

Urinary tract infection

1 (3.2)

1 (1.6)

0 (0.0)

0 (0.0)

Nervous system disorders

2 (6.5)

2 (3.2)

1 (3.2)

2 (6.5)

Headache

1 (3.2)

0 (0.0)

1 (3.2)

1 (3.2)

Dizziness

1 (3.2)

2 (3.2)

0 (0.0)

1 (3.2)

Syncope

1 (3.2)

0 (0.0)

0 (0.0)

0 (0.0)

General disorders and administration site conditions

1 (3.2)

2 (3.2)

1 (3.2)

1 (3.2)

Fatigue

1 (3.2)

1 (1.6)

1 (3.2)

0 (0.0)

Edema peripheral

0 (0.0)

0 (0.0)

0 (0.0)

1 (3.2)

Investigations

2 (6.5)

2 (3.2)

0 (0.0)

0 (0.0)

Liver palpable subcostal

1 (3.2)

0 (0.0)

0 (0.0)

0 (0.0)

Occult blood positive

1 (3.2)

0 (0.0)

0 (0.0)

0 (0.0)

Musculoskeletal and connective tissue disorders

0 (0.0)

1 (1.6)

1 (3.2)

2 (6.5)

Gouty arthritis

0 (0.0)

0 (0.0)

1 (3.2)

0 (0.0)

Back pain

0 (0.0)

0 (0.0)

0 (0.0)

2 (6.5)

Vascular disorders

0 (0.0)

4 (6.3)

0 (0.0)

0 (0.0)

Hypertension

0 (0.0)

3 (4.8)

0 (0.0)

0 (0.0)

Metabolism and nutrition disorders

0 (0.0)

2 (3.2)

0 (0.0)

1 (3.2)

Hypoglycemia

0 (0.0)

0 (0.0)

0 (0.0)

1 (3.2)

Skin and subcutaneous tissue disorders

1 (3.2)

1 (1.6)

1 (3.2)

0 (0.0)

Pruritus

0 (0.0)

0 (0.0)

1 (3.2)

0 (0.0)

Rash papular

1 (3.2)

0 (0.0)

0 (0.0)

0 (0.0)

Table 2: Summary of treatment-emergent adverse events during the treatment period .